More and more tumor-targeted drugs are not designed to destroy tumor cells, but to block the interaction between tumor cells and other cells, such as PD-1/PD-L1 monoclonal antibodies and anti-VEGF bevacizumab. Here, CD274 is linked to neoplasm.